Cowen reaffirmed their hold rating on shares of Pacira Biosciences (NASDAQ:PCRX) in a report issued on Thursday morning, AnalystRatings.com reports. The firm currently has a $41.00 price objective on the stock.
Several other equities research analysts have also issued reports on PCRX. Stifel Nicolaus set a $42.00 price objective on Pacira Biosciences and gave the company a hold rating in a research note on Friday, August 9th. Zacks Investment Research raised Pacira Biosciences from a sell rating to a hold rating and set a $47.00 price objective for the company in a research note on Friday, August 2nd. BidaskClub raised Pacira Biosciences from a sell rating to a hold rating in a research note on Wednesday. BMO Capital Markets lowered their price objective on Pacira Biosciences from $46.00 to $43.00 and set a market perform rating for the company in a research note on Friday, August 9th. Finally, Jefferies Financial Group set a $60.00 price objective on Pacira Biosciences and gave the company a buy rating in a research note on Tuesday, October 8th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. Pacira Biosciences presently has a consensus rating of Hold and a consensus price target of $52.55.
PCRX traded up $1.40 during midday trading on Thursday, reaching $44.02. The company had a trading volume of 711,200 shares, compared to its average volume of 631,161. The company has a market cap of $1.76 billion, a P/E ratio of 151.79, a P/E/G ratio of 1.96 and a beta of 1.13. The business has a 50-day moving average of $39.20 and a two-hundred day moving average of $41.12. The company has a quick ratio of 4.12, a current ratio of 4.75 and a debt-to-equity ratio of 0.99. Pacira Biosciences has a 1 year low of $34.64 and a 1 year high of $50.90.
Pacira Biosciences (NASDAQ:PCRX) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.35. The business had revenue of $104.69 million during the quarter, compared to analysts’ expectations of $104.88 million. Pacira Biosciences had a return on equity of 8.62% and a net margin of 2.04%. The firm’s revenue for the quarter was up 25.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.31 EPS. On average, equities research analysts predict that Pacira Biosciences will post 0.63 EPS for the current year.
In related news, CEO David M. Stack sold 12,849 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $39.15, for a total transaction of $503,038.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Kristen Marie Williams sold 6,252 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $39.49, for a total value of $246,891.48. The disclosure for this sale can be found here. 5.80% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the stock. Stephens Inc. AR raised its position in Pacira Biosciences by 1.8% during the 3rd quarter. Stephens Inc. AR now owns 15,935 shares of the company’s stock valued at $607,000 after purchasing an additional 287 shares in the last quarter. US Bancorp DE increased its holdings in shares of Pacira Biosciences by 9.4% in the 2nd quarter. US Bancorp DE now owns 4,373 shares of the company’s stock valued at $190,000 after acquiring an additional 375 shares during the period. Steward Partners Investment Advisory LLC increased its holdings in shares of Pacira Biosciences by 23.0% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 2,029 shares of the company’s stock valued at $77,000 after acquiring an additional 379 shares during the period. First Mercantile Trust Co. increased its holdings in shares of Pacira Biosciences by 19.5% in the 2nd quarter. First Mercantile Trust Co. now owns 4,463 shares of the company’s stock valued at $194,000 after acquiring an additional 728 shares during the period. Finally, HM Payson & Co. purchased a new position in shares of Pacira Biosciences in the 2nd quarter valued at $39,000. 99.13% of the stock is owned by hedge funds and other institutional investors.
About Pacira Biosciences
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.
Further Reading: Insider Trading – What You Need to Know
Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.